FDA Priority Review for Metastatic Melanoma Oral Combination

The combination of two oral targeted agents, dabrafenib (Tafinlar) and trametinib (Mekinist), has been given a priority review by the FDA for the treatment of BRAF V600-positive metastatic melanoma.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news